Tamara Cox, MD
Family Medicine · Brownwood, TXNPI 1558359976
Payments from drug & device makers
Across 270 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1000
- AstraZeneca$857
- Novo Nordisk$414
- Pfizer$339
- Boehringer Ingelheim$222
- Lilly USA, LLC$186
- plus $801 from 15 others
What the payments were for
- Food & beverage$3,819100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,000 |
| AstraZeneca | 53 | $857 |
| Novo Nordisk | 28 | $414 |
| Pfizer | 18 | $339 |
| Boehringer Ingelheim | 13 | $222 |
| Lilly USA, LLC | 13 | $186 |
| Johnson & Johnson | 8 | $126 |
| Amgen | 9 | $120 |
| Merck | 7 | $98 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| GSK | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Exact Sciences | 3 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $26 |
| Eisai Inc. | 2 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Corium, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,819 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $54,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $49,038 |
| JanuviaSitagliptin Phosphate | 31 | $39,822 |
| OzempicSemaglutide | 20 | $35,504 |
| XareltoRivaroxaban | 25 | $28,979 |
| FarxigaDapagliflozin Propanediol | 44 | $27,471 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $15,312 |
| MyrbetriqMirabegron | 11 | $9,083 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,837 |
| JardianceEmpagliflozin | 11 | $6,684 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,995 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 195 | $4,716 |
| Levothyroxine Sodium | 358 | $4,210 |
| SynthroidLevothyroxine Sodium | 54 | $3,659 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $3,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $339 | $54,30166 claims |
| GSKTrelegy Ellipta | $70 | $49,03835 claims |
| MerckJanuvia | $98 | $39,82231 claims |
| Novo NordiskOzempic | $414 | $35,50420 claims |
| Johnson & JohnsonXarelto | $126 | $28,97925 claims |
| AstraZenecaFarxiga | $857 | $27,47144 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $9,08311 claims |
| Boehringer IngelheimJardiance | $222 | $6,68411 claims |
| AbbVieSynthroid | $1,000 | $3,65954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Brownwood
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.